Paper test strip could help heart failure patients monitor their condition at home

May 24, 2017

Contrary to the condition's name, heart failure doesn't mean the heart has stopped pumping -- it's just not working at full strength. It can often be managed with medications and lifestyle changes, but its progression needs to be monitored closely. Now scientists have developed a new test strip that could potentially allow patients to do this at home for the first time. Their study appears in the journal ACS Nano.

In the U.S., nearly 6 million people live with heart failure, and about 1 million hospitalizations occur each year are related to the condition, according to the American Heart Association. Closely tracking the condition after diagnosis is important for adjusting treatment and preventing emergency room visits. Antigens called ST2 and BNP are good indicators of heart failure and how it's progressing. But currently, analyzing the levels of these biomarkers requires both trained personnel and sophisticated lab equipment. Feng Xu, Min Lin and colleagues wanted to devise a simple test to enable doctors and patients to carry out the same analysis at the office or at home.

The researchers developed a paper-based test that requires only a small blood sample of 10 microliters. A blue dot glows on the strip if ST2 is present in the sample, and a green dot glows if it contains BNP. The colors' intensities increase with concentration, which indicates a person's heart failure is likely becoming worse. A smartphone app can analyze the readout and send the results to the patient's doctor, who can adjust the patient's treatment accordingly. Testing 38 serum samples from people with heart failure showed that the paper test closely matched conventional techniques.
-end-
The authors acknowledge funding from the National Natural Science Foundation of China, the International Science & Technology Cooperation Program of China, the National Instrumentation Program (China), the Fundamental Research Funds for the Central Universities and the Open Funding Project of Key Laboratory of Space Nutrition and Food Engineering Laboratory.

The abstract that accompanies this study is available here.

The American Chemical Society, the world's largest scientific society, is a not-for-profit organization chartered by the U.S. Congress. ACS is a global leader in providing access to chemistry-related information and research through its multiple databases, peer-reviewed journals and scientific conferences. ACS does not conduct research, but publishes and publicizes peer-reviewed scientific studies. Its main offices are in Washington, D.C., and Columbus, Ohio.

To automatically receive news releases from the American Chemical Society, contact newsroom@acs.org.

Follow us on Twitter | Facebook

American Chemical Society

Related Heart Failure Articles from Brightsurf:

Top Science Tip Sheet on heart failure, heart muscle cells, heart attack and atrial fibrillation results
Newly discovered pathway may have potential for treating heart failure - New research model helps predict heart muscle cells' impact on heart function after injury - New mass spectrometry approach generates libraries of glycans in human heart tissue - Understanding heart damage after heart attack and treatment may provide clues for prevention - Understanding atrial fibrillation's effects on heart cells may help find treatments - New research may lead to therapy for heart failure caused by ICI cancer medication

Machining the heart: New predictor for helping to beat chronic heart failure
Researchers from Kanazawa University have used machine learning to predict which classes of chronic heart failure patients are most likely to experience heart failure death, and which are most likely to develop an arrhythmic death or sudden cardiac death.

Heart attacks, heart failure, stroke: COVID-19's dangerous cardiovascular complications
A new guide from emergency medicine doctors details the potentially deadly cardiovascular complications COVID-19 can cause.

Autoimmunity-associated heart dilation tied to heart-failure risk in type 1 diabetes
In people with type 1 diabetes without known cardiovascular disease, the presence of autoantibodies against heart muscle proteins was associated with cardiac magnetic resonance (CMR) imaging evidence of increased volume of the left ventricle (the heart's main pumping chamber), increased muscle mass, and reduced pumping function (ejection fraction), features that are associated with higher risk of failure in the general population

Transcendental Meditation prevents abnormal enlargement of the heart, reduces chronic heart failure
A randomized controlled study recently published in the Hypertension issue of Ethnicity & Disease found the Transcendental Meditation (TM) technique helps prevent abnormal enlargement of the heart compared to health education (HE) controls.

Beta blocker use identified as hospitalization risk factor in 'stiff heart' heart failure
A new study links the use of beta-blockers to heart failure hospitalizations among those with the common 'stiff heart' heart failure subtype.

Type 2 diabetes may affect heart structure and increase complications and death among heart failure patients of Asian ethnicity
The combination of heart failure and Type 2 diabetes can lead to structural changes in the heart, poorer quality of life and increased risk of death, according to a multi-country study in Asia.

Preventive drug therapy may increase right-sided heart failure risk in patients who receive heart devices
Patients treated preemptively with drugs to reduce the risk of right-sided heart failure after heart device implantation may experience the opposite effect and develop heart failure and post-operative bleeding more often than patients not receiving the drugs.

How the enzyme lipoxygenase drives heart failure after heart attacks
Heart failure after a heart attack is a global epidemic leading to heart failure pathology.

Novel heart pump shows superior outcomes in advanced heart failure
Severely ill patients with advanced heart failure who received a novel heart pump -- the HeartMate 3 left ventricular assist device (LVAD) -- suffered significantly fewer strokes, pump-related blood clots and bleeding episodes after two years, compared with similar patients who received an older, more established pump, according to research presented at the American College of Cardiology's 68th Annual Scientific Session.

Read More: Heart Failure News and Heart Failure Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.